search
Back to results

A Study to Reduce Persistent Post-mastectomy Pain Using Opioid-free Anesthesia (RELIEF)

Primary Purpose

Breast Cancer, Mastectomy, Pain, Chronic

Status
Recruiting
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Opioid-free anesthesia
Conventional opioid-based anesthesia
Sponsored by
Gangnam Severance Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Breast Cancer

Eligibility Criteria

19 Years - 80 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • All of patients will undergo mastectomy with or without immediate breast reconstruction.

Exclusion Criteria:

  • Previous history of breast surgery
  • Allergy to drug
  • Other cancer history
  • Underlying psychologic disorder
  • Patients with chronic pain requiring pain killers
  • Baseline SpO2 <95%
  • Left ventricular EF <40%
  • Bradycardia as HR <50 bpm
  • BMI >35kg/m2
  • Pregnant woman

Sites / Locations

  • Gangnam Severance HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Opioid-free anesthesia group

Conventional anesthesia group with opioid

Arm Description

OFA group will be sedated using dexmedetomidine and lidocaine during mastectomy.

Conventional opioid anesthesia group will be sedated using remi-fentanyl during mastectomy.

Outcomes

Primary Outcome Measures

Presence of chronic breast pain at 1 year after mastectomy
Presence of chronic pain will be assessed by Breast Cancer Pain Questionnaire (BCPQ). Zero score means absence of persisting breast-related pain. The minimum and maximum values of pain scale are 0 and 11, respectively. High score means worse outcome.

Secondary Outcome Measures

Quality of life
Presence of anxiety and depression symptoms will be assessed by HADS (Hospital Anxiety and Depression Scale) questionnaire. The range of each symptoms scale is between 0 and 21. A scale of 0-7 is defined as normal, a scale of 8-10 is defined as borderline, and a scale of 11-21 is defined as abnormal. High score means worse outcome.
Pain Sensitivity
The type of pain will be assessed by painDetect Questionnaire (PDQ). The PDQ comprises 12 items. The first three assess current pain, strongest pain during the past 4 weeks, and average pain during the past 4 weeks on a 0-10 point numerical rating scale from "none" to "worst imaginable".

Full Information

First Posted
September 23, 2021
Last Updated
March 24, 2022
Sponsor
Gangnam Severance Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05146778
Brief Title
A Study to Reduce Persistent Post-mastectomy Pain Using Opioid-free Anesthesia
Acronym
RELIEF
Official Title
A Single-blinded Randomized-controlled Study to Reduce Persistent Post-mastectomy Pain Using Multimodal Opioid-free Anesthesia
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 16, 2021 (Actual)
Primary Completion Date
October 31, 2024 (Anticipated)
Study Completion Date
October 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Gangnam Severance Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In 230 patients undergoing mastectomy, the investigators will compare opioid-free anesthesia (OFA) versus conventional opioid-based anesthesia in terms of chronic pain. The enrolled patients will be randomly assigned into two groups with 1:1 ratio. Chronic pain will be evaluated at 1 year after mastectomy based on the Breast Cancer Pain Questionnaire (BCPQ). Baseline pain sensitivity test and psychologic evaluation will be done before operation.
Detailed Description
Study population All of patients will undergo mastectomy with or without immediate breast reconstruction. 230 patients will be enrolled. Intervention OFA group will be sedated using dexmedetomidine and lidocaine. Conventional opioid anesthesia group will be sedated using remifentanil. Pain screening Breast Cancer Pain Questionnaire (BCPQ) Pain-detect, HADS, EQ-5D, PHQ-15 (somatic symptom), PCS (pain catastrophizing), BFI (big five inventory), HAM-A&D, Pressure algometry (Pain sensitivity), Quantitative sensory test (pinprick)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer, Mastectomy, Pain, Chronic, Pain, Post Operative

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Control arm: Conventional Anesthesia with opioid Interventional arm: Opiod-free Anesthesia with dexmedetomidine and lidocaine
Masking
Participant
Masking Description
Patients will be not aware of which type of anesthesia would be applied during operation.
Allocation
Randomized
Enrollment
230 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Opioid-free anesthesia group
Arm Type
Active Comparator
Arm Description
OFA group will be sedated using dexmedetomidine and lidocaine during mastectomy.
Arm Title
Conventional anesthesia group with opioid
Arm Type
Active Comparator
Arm Description
Conventional opioid anesthesia group will be sedated using remi-fentanyl during mastectomy.
Intervention Type
Procedure
Intervention Name(s)
Opioid-free anesthesia
Other Intervention Name(s)
Dexmedetomidine and lidocaine-based anesthesia
Intervention Description
OFA group will be sedated using dexmedetomidine and lidocaine.
Intervention Type
Procedure
Intervention Name(s)
Conventional opioid-based anesthesia
Other Intervention Name(s)
Remi-fentanyl
Intervention Description
Conventional opioid-based anesthesia group will be sedated using remi-fentanyl
Primary Outcome Measure Information:
Title
Presence of chronic breast pain at 1 year after mastectomy
Description
Presence of chronic pain will be assessed by Breast Cancer Pain Questionnaire (BCPQ). Zero score means absence of persisting breast-related pain. The minimum and maximum values of pain scale are 0 and 11, respectively. High score means worse outcome.
Time Frame
1 year after mastectomy
Secondary Outcome Measure Information:
Title
Quality of life
Description
Presence of anxiety and depression symptoms will be assessed by HADS (Hospital Anxiety and Depression Scale) questionnaire. The range of each symptoms scale is between 0 and 21. A scale of 0-7 is defined as normal, a scale of 8-10 is defined as borderline, and a scale of 11-21 is defined as abnormal. High score means worse outcome.
Time Frame
1 year after mastectomy
Title
Pain Sensitivity
Description
The type of pain will be assessed by painDetect Questionnaire (PDQ). The PDQ comprises 12 items. The first three assess current pain, strongest pain during the past 4 weeks, and average pain during the past 4 weeks on a 0-10 point numerical rating scale from "none" to "worst imaginable".
Time Frame
1 year after mastectomy

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All of patients will undergo mastectomy with or without immediate breast reconstruction. Exclusion Criteria: Previous history of breast surgery Allergy to drug Other cancer history Underlying psychologic disorder Patients with chronic pain requiring pain killers Baseline SpO2 <95% Left ventricular EF <40% Bradycardia as HR <50 bpm BMI >35kg/m2 Pregnant woman
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sung Gwe Ahn, M.D.,Ph.D.
Phone
82220194402
Email
asg2004@yuhs.ac
First Name & Middle Initial & Last Name or Official Title & Degree
Soong June Bae, M.D.
Phone
82220193370
Email
mission815815@yuhs.ac
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sung Gwe G Ahn, M.D.,Ph.D.
Organizational Affiliation
Gangnam Severance Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gangnam Severance Hospital
City
Seoul
ZIP/Postal Code
135270
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sung Gwe Ahn, MD, PhD
Phone
82-2-2019-3370
Email
asg2004@yuhs.ac

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study to Reduce Persistent Post-mastectomy Pain Using Opioid-free Anesthesia

We'll reach out to this number within 24 hrs